BUSINESS

Medipal’s Subsidiary to Distribute Stemirac in Japan

April 9, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Medipal Holdings said on April 8 that its subsidiary SPLine and Nipro entered into a distribution agreement for Nipro’s stem cell therapy Stemirac for spinal cord injury (SCI) in Japan during its conditional, time-limited approval period. With Stemirac, mesenchymal stem…

To read the full story

Nipro Files for Full Approval of Stemirac Cell Therapy
November 18, 2025
Stemirac Fetches 15 Million Yen Price Tag, Peak Sales Put at 3.7 Billion Yen
February 20, 2019
Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
December 28, 2018

BUSINESS

Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026
Minimum Price Hike, Spillover Abolition Win Industry Support in FY2026 Reform: Jiho Poll
March 10, 2026
Xospata Misses OS Endpoint in PIII Trial in Untreated FLT3-Mutated AML
March 10, 2026
Enhertu Now under US Review for Post-Neoadjuvant HER2 Breast Cancer
March 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

ICH Weighs Need for Biosimilar Efficacy Trials as Regulators Move Away from Routine Use

By Takashi Ebisawa

International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…